Format

Send to

Choose Destination
Cell Death Differ. 2017 May;24(5):889-902. doi: 10.1038/cdd.2017.34. Epub 2017 Mar 24.

Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.

Author information

1
Liver Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
2
UOSD SAFU, Regina Elena National Cancer Institute, Rome, Italy.
3
Fondazione Bruno Kessler, Trento, Italy.
4
Department of Oncohematology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
5
Microscopy Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
6
FACs Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
7
Department of Experimental Oncology, European Institute of Oncology, Milan, Italy.
8
Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy.
9
Gastroenterology, Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy.
10
Institute of Molecular Biology and Pathology, National Research Council, Rome, Italy.
11
University of Pavia, Pavia, Italy.
12
Hepato-Metabolic Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Abstract

Hepatocellular carcinoma (HCC) is the most common type of liver cancer in humans. The focal adhesion tyrosine kinase (FAK) is often over-expressed in human HCC and FAK inhibition may reduce HCC cell invasiveness. However, the anti-oncogenic effect of FAK knockdown in HCC cells remains to be clarified. We found that FAK depletion in HCC cells reduced in vitro and in vivo tumorigenicity, by inducing G2/M arrest and apoptosis, decreasing anchorage-independent growth, and modulating the expression of several cancer-related genes. Among these genes, we showed that FAK silencing decreased transcription and nuclear localization of enhancer of zeste homolog 2 (EZH2) and its tri-methylation activity on lysine 27 of histone H3 (H3K27me3). Accordingly, FAK, EZH2 and H3K27me3 were concomitantly upregulated in human HCCs compared to non-tumor livers. In vitro experiments demonstrated that FAK affected EZH2 expression and function by modulating, at least in part, p53 and E2F2/3 transcriptional activity. Moreover, FAK silencing downregulated both EZH2 binding and histone H3K27me3 levels at the promoter of its target gene NOTCH2. Finally, we found that pharmacological inhibition of FAK activity resembled these effects although milder. In summary, we demonstrate that FAK depletion reduces HCC cell growth by affecting cancer-promoting genes including the pro-oncogene EZH2. Furthermore, we unveil a novel unprecedented FAK/EZH2 crosstalk in HCC cells, thus identifying a targetable network paving the way for new anticancer therapies.

PMID:
28338656
PMCID:
PMC5423113
DOI:
10.1038/cdd.2017.34
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center